Abstract: A cell culture medium for culturing organoid containing at least two types of components selected from the group consisting of insulin-like growth factor 1 (IGH1), fibroblast growth factor 2 (FGF2) and epiregulin (EREG), and at least one type of component among the following components i (to III); i) Wnt agonist, ii) bone morphogenetic protein (BMP) inhibitor, and iii) transforming growth factor-? (TGIF-?) inhibitor.

Abstract: The present invention provides a therapeutic agent for an immune/inflammatory disease comprising an anti-human TIGIT antibody, which activates a suppressive immune checkpoint molecule (TIGIT), as an active ingredient. Also, provided is an antibody having the following characteristics a) and b): a) the third CDR of heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 4 b) the third CDR of light chain variable region comprises the amino acid sequence of SEQ ID NO: 6.

Abstract: An antibody against spike protein of SARS-CoV-2 is provided, the antibody having a specific heavy chain variable region and a specific light chain variable region, or a fragment of the antibody, the antibody or fragment thereof inhibiting the binding between the spike protein of SARS-CoV-2 and ACE2, the antibody or fragment thereof inhibiting SARS-CoV-2 infection; and a pharmaceutical composition including the antibody or fragment thereof and a pharmaceutically acceptable carrier, the pharmaceutical composition including two or more kinds of the antibody or fragment thereof.

Abstract: A supporting body includes a cluster of an alloy containing Pt and Co, and a support on which the cluster is supported. An amount of Pt supported is 1×10?14 ng/cm2 or more and 1×105 ng/cm2 or less.

Abstract: A finger exerciser includes: a frame on which a palm of a subject to be put; a movable section; a first fixing element; and a second fixing element. The movable is configured to move a first finger group of a subject. The first fixing element is configured to fix a position of the first finger group to the movable section. The second fixing element is configured to fix a position of a second finger group to the frame and has a band-like member including at least two attachment parts apart from each other in a longitudinal direction of the band-like member. The band-like member is attached to the frame at the attachment parts and includes a holder whose location to the frame is changeable. The band-like member is configured to hold the second finger group in a state where the band-like member is attached to the frame.

Abstract: The present invention is intended to provide a medicament for cyanide poisoning, hydrogen sulfide poisoning, and azide poisoning, wherein the medicament does not cause side effects, is excellent in immediate effectiveness, and has a high antidotal effect. Specifically, the present invention relates to a medicament for cyanide poisoning, hydrogen sulfide poisoning, and azide poisoning, wherein the medicament comprises, as an active ingredient(s), one or more selected from the group consisting of a heme protein capable of binding to cyanide ions (CN?), hydrogen sulfide ions (HS?) and azide ions (N3?), a substance containing a heme protein capable of binding to CN?, HS? and N3?, and a heme derivative capable of binding to CN?, HS? and N3?. More specifically, the present invention relates to a medicament or a pharmaceutical composition for the treatment or prophylaxis of cyanide poisoning, hydrogen sulfide poisoning, and azide poisoning.

Abstract: The result of orally administering saliva derived from a Crohn’s disease patient or an ulcerative colitis patient to germ-free mice has revealed that Th1 cells markedly increased in the colons. Further, from the bacterial microbiota in the intestines of the mice in which such an increase in Th1 cells were observed, bacteria have been successfully isolated which caused strong Th1 cell induction in the colon upon intestinal colonization.

Abstract: An object of the present invention is to regulate the number of peripheral regulatory T cells in the gut and establish a novel therapeutic approach for a disease related to the cells. The present invention provides a therapeutic agent for a disease, comprising a substance having an effect of regulating an amount of peripheral regulatory T cells in the gut, wherein the substance is a substance activating or inhibiting afferent pathway of the hepatic branch of the vagus nerve, a substance activating or inhibiting efferent pathway of the left vagus nerve, or an agonist or an antagonist of a muscarinic acetylcholine receptor.

Abstract: A cell culture medium for culturing organoid containing at least two types of components selected from the group consisting of insulin-like growth factor 1 (IGH1), fibroblast growth factor 2 (FGF2) and epiregulin (EREG), and at least one type of component among the following components i (to III); i) Wnt agonist, ii) bone morphogenetic protein (BMP) inhibitor, and iii) transforming growth factor-? (TGIF-?) inhibitor.

Abstract: An arithmetic processing apparatus includes a controlling unit that refers to an attribute of a compressing scheme on data on a main memory when the data is transferred between the main memory and a memory controller, and that transfers the data by switching the compressing scheme based on the referred attribute.

Abstract: There is provided the turbulence prediction system or the turbulence prediction method that predicts a zone in a prediction area where the possibility of the occurrence of a turbulence is high at a determination time point.

Abstract: An implant installation strength evaluation method includes a step of vibrating an implant, a step of measuring time series data of the number of vibrations and vibration strengths of the implant vibrated in the vibrating step, and a step of deriving information indicating an index of an installation strength of the implant based on the time series data of the number of vibrations and vibration strengths of the implant.

Abstract: A control system includes a master device, a slave device, and a control device that controls the master device and the slave device. In the control device, a response value acquisition unit acquires data of physical quantities representing action of the movable portion of the master device, and data of physical quantities representing action of the movable portion of the slave device. A command value calculation unit hypothesizes a virtual object that includes the master device and the slave device, and calculates a command value for causing the master device and the slave device to follow behavior expressed in the virtual object by input to the master device and the slave device, on the basis of the data of physical quantities acquired by the response value acquisition unit.

Abstract: An information processing apparatus acquires a first verifiable credential (VC) that proves the validity of attribute information of a holder by a first signature verifiable by verification procedures of a first decentralized identifiers (DID) infrastructure and a second VC that proves the validity of the attribute information of the holder by a second signature verifiable by verification procedures of a second DID infrastructure. Next, the information processing apparatus verifies the second signature contained in the second VC by the verification procedures of the second DID infrastructure. Further, the information processing apparatus transmits a verification request for verifying the first signature contained in the first VC to a verification device capable of verifying the first signature contained in the first VC by the verification procedures of the first DID infrastructure, and then acquires, from the verification device, verification results of the first signature contained in the first VC.

Abstract: A method of culturing human induced pluripotent stem cells includes inoculating human induced pluripotent stem cells in a culture medium at an inoculation density of 1.0×104 to 1.0×106 cells/cm2 in a culture vessel and subjecting the human induced pluripotent stem cells to two-dimensional culturing. A method of producing cerebral organoids includes culturing a culture of the human induced pluripotent stem cells obtained by the method of culturing human induced pluripotent stem cells in a culture medium containing a BMP inhibitor and a transforming growth factor ? (TGF?) inhibitor to form cell aggregates, culturing the cell aggregates in a culture medium containing a Wnt signal transduction pathway potentiator and an extracellular matrix, and subjecting the culturing obtained in the culturing the cell aggregates to spinner culturing.

Abstract: Provided herein are compositions and methods for the induction and/or proliferation of CD8+ T-cells. The disclosure also provides methods of treatment of diseases that can be treated by the induction and/or proliferation of CD8+ T-cells.

Abstract: A reagent for differentiating somatic cells into alveolar epithelial cells includes an NK2 homeobox family gene expression vector, and a Fox family gene expression vector, a method for manufacturing alveolar epithelial cells, the method including forcing a somatic cell to express an NK2 homeobox family gene and a Fox family gene and culturing the somatic cell after forced expression, an alveolar epithelial cell manufactured by the manufacturing method, and a cell medicine including the alveolar epithelial cell.

Abstract: An object of the present invention is to provide, for example, a more practical wound healing accelerator that more effectively accelerates wound healing. More specifically, a feature of the present invention is to provide, for example, a more practical wound healing accelerator that is easily obtained in a larger amount than that of peripheral blood platelet and has a better wound healing effect than that of peripheral blood platelet. The present invention employs a platelet-like cell population coexpressing one or more platelet surface markers and one or more mesenchymal cell surface markers. A wound healing accelerator containing the platelet-like cell population is a more practical wound healing accelerator that more effectively accelerates wound healing. The platelet-like cell population is easily obtained in a larger amount than that of peripheral blood platelet and has a better wound healing effect than that of peripheral blood platelet.

Abstract: A human tissue stem cell in which a gene of interest is introduced into a gene locus of a stem cell marker gene.

Abstract: A method is provided for producing astrocyte-like cells, including (A) upregulating transcription factors including SRY-box transcription factor 9 (SOX9), nuclear factor IA (NFIA), and nuclear factor IB (NFIB) in human pluripotent stein cells and (B) culturing the human pluripotent stem cells, in which the transcription factors are upregulated, and consequently differentiating the human pluripotent stern cells into astrocyte-like cells.